US › Healthcare

HCW Biologics Inc (HCWB)

US · Healthcare · Biotechnology

$1.95-2.99%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$135,568

Revenue YoY

+1969.7%

Net profit

$-5.2M

EPS

$-10.10

EPS estimate

$-1.98

Net margin

-3,849.9%

EPS came in at -10.10 against a street estimate of -1.98 — a miss of 410.1%.

Key statistics

Market cap

$4.1M

Forward P/E

0.0

P/B

0.55

Book value

$4.59

EPS (TTM)

$-16.62

52-week high

$30.84

52-week low

$1.50

50-day MA

$3.24

200-day MA

$5.54

Beta

2.38

Analyst view

Analysts rate HCW Biologics Inc a buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $30.00.

Shareholding

Insiders

9.72%

Institutions

9.03%

Largest institutional holders

Fund	Stake
HRT FINANCIAL LLC	2.45%
Virtu Financial LLC	0.44%
Geode Capital Management, LLC	0.33%
Citadel Advisors Llc	0.18%
Tower Research Capital LLC	0.14%
Jane Street Group LLC	0.13%
Vanguard Capital Management, LLC	0.11%
Citigroup Inc	0.10%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for HCW Biologics Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.